Fresenius stock holds above EUR 44.83 after Q2 2026 progress

Published on 09/04/2026 at 18:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius stock held near EUR 44.83 on Xetra as Q2 2026 progress and a 25 billion euro market value kept the MDAX group in view.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius stock (ISIN DE0005785604) traded at EUR 44.83 on Xetra on September 2, 2026, with a market capitalization of EUR 25.0 billion. The move came as a current market overview pointed to a Q2 2026 recovery story for the MDAX healthcare group.

Q2 figures stay in view

According to the same ad-hoc-news.de overview, Fresenius reported Q2 2026 revenue growth and improving operating profit, with sales up in the mid-single-digit percent range and earnings expanding faster. The article also notes that the group was still being measured against earlier restructuring pressure.

That comparison matters for investors because the latest quarter is now the relevant yardstick: the stock is priced in the mid-40-euro range, while the company is still being judged on whether margin gains can keep pace with revenue growth.

MDAX valuation context

The share price of EUR 44.83 on September 2, 2026 sits well above the lows seen during the restructuring phase and below the 52-week high referenced in the market overview. With 126,110 shares traded in one of the cited quote snapshots, the name remained active in German market trading.

In market terms, the key comparison is clear: a EUR 44.83 share price against a EUR 25.0 billion valuation leaves Fresenius tied to execution in 2026, not to a distant turnaround story.

Go deeper

More background on Fresenius stock

The company overview on ad-hoc-news.de adds the latest quote context, the listed venue and the current valuation frame for Fresenius investors.

All news on DE0005785604

Helios remains central

Helios remains one of Fresenius' central operating pillars, linking German hospital operations with the groupwide earnings base. That segment focus is one reason the market keeps watching margin progress as closely as revenue growth.

Stock level and venue

Fresenius stock closed the cited snapshot at EUR 44.83 on Xetra in Frankfurt on September 2, 2026, while the market capitalization stood at EUR 25.0 billion. The combination leaves the MDAX healthcare group priced as a large-cap recovery story rather than a pure defensive name.